ArticleACS medicinal chemistry letters2024
Novel Approaches for Upregulation of Tumor Suppressor Proteins: Pioneering Strategies and Integrative Potentials.
Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In cancer therapy, the modulation of tumor suppressor proteins represents a critical frontier in developing innovative treatments. A promising direction in this field is the strategic upregulation of tumor suppressor proteins, a paradigm illustrated by the development of compounds designed to enhance the activity of the p53 protein. This protein, often called the "guardian of the genome", is crucial in preventing cancer development by inducing cell cycle arrest, apoptosis, and senescence in response to DNA damage and oncogenic stress. However, p53 function is compromised in many cancers, leading to unchecked cell proliferation and tumor progression. Addressing this challenge, a novel approach focuses on manipulating the p53/MDM2 signaling pathway to restore p53's tumor-suppressive functions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.